Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2020 - 07 - 09

Menarini Ricerche Announces the Latest Findings of its Vaborem™ and Quofenix™ Clinical Studies

Pomezia (Italy), July 9th, 2020 – Menarini Ricerche, the R&D division of the Menarini Group, announces that it has published four abstracts presenting the latest findings related to its meropenem/vaborbactam (Vaborem) and delafloxacin (Quofenix) clinical studies, confirming Menarini’s commitment to fighting life-threatening bacterial infections. The findings are included in the abstract book of the ECCMID, available at

The successful findings of the clinical studies are the result of the fruitful partnership between Menarini and Melinta Therapeutics. These findings provide important new insights into the infectious disease area related to a number of topics, including: hospital acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP) due to Carbapenem resistant Enterobacteriaceae (CRE); difficult-to-treat subjects with Acute Bacterial Skin and Skin-Structure Infections (ABSSSI);  European patients with community acquired bacterial pneumonia (CABP); and Quofenix microbiological activity against clinical isolates causative of CABP.

“Every year infections related to antibiotic-resistant pathogens kill 700,000 people worldwide, of which 33,000 are in Europe”, commented Angela Capriati, Global Corporate Director of Clinical Sciences and Therapeutic Area Head, General Medicine, Menarini Ricerche. “If we don’t take concrete actions to fight against the worrying spread of antimicrobial resistance, some forecasts show that infections could kill up to 10 million people by 2050, a higher number than the people currently dying from cancer. That is why Menarini Ricerche is fully committed in bringing new treatments for difficult-to-treat and hospital acquired infections for the most fragile patients, focusing on multidrug resistant pathogens, which the World Health Organization lists as serious threats to global public health”.

Below is a summary of the findings presented in the ECCMID abstract book.

The first abstract is dedicated to Vaborem, the first carbapenem/β-lactamase inhibitor combination, developed to selectively tackle CRE thanks to the strong activity against Class A and C serine β-lactamases1. The data reported in the abstract relies on the results of the TANGO II trial, the first pathogen-specific study addressing patients with CRE infections. In this randomized, Phase 3, open-label study, Vaborem was administered as monotherapy in patients with confirmed or suspected CRE infections and compared to the best available treatment, which in most cases were combinations of multiple antibiotics. Throughout the study, Vaborem showed a reduction in mortality and improvement in clinical cure and safety/tolerability over best available treatment, appearing to be an effective therapeutic option for HABP/VABP and bacteremia due to CRE.

The other three abstracts present data on Quofenix, the innovative anionic fluoroquinolone antibiotic with Gram-positive/Methicillin-Resistant Staphylococcus aureus strains (MRSA), Gram-negative and atypical activity, available as IV and oral formulations.

A post hoc analysis of pooled data from Phase 3 ABSSSI trials assessed the impact of risk factors such as age, diabetic status or type of infection on the efficacy of Quofenix2. The data reported in the abstract demonstrates that the number of risk factors does not affect the efficacy of Quofenix in ABSSSI patients, with a high success rate confirmed also in difficult-to-treat patients.

The last two abstracts refer to a recently completed global Phase 3 trial in 859 patients with CABP comparing Quofenix to moxifloxacin. Quofenix demonstrated comparable efficacy to moxifloxacin for the treatment of patients with moderate to severe CABP (PORT class III-V).  Quofenix has FQ class warnings, but the data confirms its favourable safety and tolerability profile without the potential for QT prolongation, phototoxicity, or major drug-drug interactions3.

Additional microbiological data that demonstrates potent in vitro activity and clinical efficacy of Quofenix against CABP pathogens, including S. pneumoniae, MRSA, Haemophilus species, Enterobacteriaceae, P. aeruginosa, and the atypical pathogens C. pneumoniae, M. pneumoniae and L. pneumophila4 was presented in the fourth abstract.


  1. M. Bassetti, F. Menichetti, G. Daikos, S. Cammarata, K. Fusaro, D. Zinzi. Meropenem-Vaborbactam (VABOREM) in treatment of patients with hospital- and ventilator-acquired pneumonia (HABP/VABP) and bacteraemia due to carbapenem-resistant Enterobacteriaceae. (ECCMID 2020 accepted abstract 1192).
  2. B. Pizà Vallespir, S. Biliotti, A. Nizzardo, A. Nuti, S. Cammarata, D. Zinzi. Risk factors (derived from host, pathogen and disease) did not affect the efficacy of delafloxacin monotherapy in acute bacterial skin and skin structure infections trials. (ECCMID 2020 accepted abstract 7976).
  3. Alvarez-Sala, M. Popescu, L. Lawrence, S. Cammarata, D. Zinzi. Delafloxacin (DLX) in the treatment of communityacquired bacterial pneumonia (CABP): patients with PORT Risk Class III-V R. (ECCMID 2020 accepted abstract 4540).
  4. S. Mccurdy, L. Lawrence, S. Cammarata, A. Nuti, D. Zinzi. Analysis of the microbiological data from the delafloxacin (DLX) phase III community-acquired bacterial pneumonia (CABP) trial using European analysis sets. (ECCMID 2020 accepted abstract 3857).